U.S. Government Sides with Teva in Skinny Label SCOTUS Fight
Briefly

"A generic manufacturer's labeling cannot provide the requisite evidence of specific intent to induce infringement in a case like this one, where the generic manufacturer has carved out the specific indication identified by the brand-name manufacturer as corresponding to the patented method of use that is alleged to be infringed."
Read at IPWatchdog.com | Patents & Intellectual Property Law
[
add
]
[
|
|
]